Analysis of the clinical efficacy and safety of anti‐PD‐1 immune checkpoint inhibitors in locally advanced nasopharyngeal cancer
Abstract Objective To analyze the efficacy and adverse effects of anti‐PD‐1 immune checkpoint inhibitors aimed at nasopharyngeal carcinoma (NPC). Methods During the first stage of the study, using 40 patients with stage III/IVa NPC treated with anti‐PD‐1 immune checkpoint inhibitors in combination w...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-07-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.7359 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846115493438554112 |
|---|---|
| author | Shuling Shi Bingyan Li Pengcheng Zhou Linhui Chen Huizhen Li Yingyi Wang Xiaoyu Deng Qianqian Dang Jingjing Wu Boya Zha Peihong Li Yingjuan Zheng Daoke Yang |
| author_facet | Shuling Shi Bingyan Li Pengcheng Zhou Linhui Chen Huizhen Li Yingyi Wang Xiaoyu Deng Qianqian Dang Jingjing Wu Boya Zha Peihong Li Yingjuan Zheng Daoke Yang |
| author_sort | Shuling Shi |
| collection | DOAJ |
| description | Abstract Objective To analyze the efficacy and adverse effects of anti‐PD‐1 immune checkpoint inhibitors aimed at nasopharyngeal carcinoma (NPC). Methods During the first stage of the study, using 40 patients with stage III/IVa NPC treated with anti‐PD‐1 immune checkpoint inhibitors in combination with chemoradiotherapy as a first‐line treatment (observation group) and 70 patients with NPC treated with chemoradiotherapy alone (control group). In the second stage of the study, 88 patients with NPC treated with immune checkpoint inhibitors were grouped according to the number of lines of immunotherapy, the number of times, and the types of application. Results Observation of the short‐term effects in the first stage indicated that the objective response rate (ORR) of the observation group and the control group against primary foci of NPC was 75.0% versus 40.0%; the mortality rate of the observation group was much lower than that of the control group. The overall first‐line treatment evaluation of the observation vs. control groups were as follows: ORR (67.5% vs. 38.6%); median PFS (17.52 vs. 17.21 months); and median OS (18.68 vs. 18.14 months), respectively (p < 0.05). The second stage of the study had an ORR of 53.4%, and the efficacy of immunotherapy was related to staging, timing, and frequency. Conclusion Anti‐PD‐1 immune checkpoint inhibitors combined with chemoradiotherapy as the first‐line treatment for nasopharyngeal carcinoma may improve patient outcomes significantly. Timing, frequency, and the type of immunotherapy exerted an effect on the efficacy of immunotherapy. Adverse effects that occurred during treatment were tolerable and controllable. |
| format | Article |
| id | doaj-art-eb1bcefdabd34e0c98f940afcf24f7a5 |
| institution | Kabale University |
| issn | 2045-7634 |
| language | English |
| publishDate | 2024-07-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj-art-eb1bcefdabd34e0c98f940afcf24f7a52024-12-19T12:33:08ZengWileyCancer Medicine2045-76342024-07-011314n/an/a10.1002/cam4.7359Analysis of the clinical efficacy and safety of anti‐PD‐1 immune checkpoint inhibitors in locally advanced nasopharyngeal cancerShuling Shi0Bingyan Li1Pengcheng Zhou2Linhui Chen3Huizhen Li4Yingyi Wang5Xiaoyu Deng6Qianqian DangJingjing Wu7Boya Zha8Peihong Li9Yingjuan Zheng10Daoke Yang11Department of Radiation Oncology The First Affiliated Hospital of Zhengzhou University Zhengzhou Henan ChinaDepartment of Radiation Oncology The First Affiliated Hospital of Zhengzhou University Zhengzhou Henan ChinaDepartment of Radiation Oncology The First Affiliated Hospital of Zhengzhou University Zhengzhou Henan ChinaDepartment of Radiation Oncology The First Affiliated Hospital of Zhengzhou University Zhengzhou Henan ChinaDepartment of Radiation Oncology The First Affiliated Hospital of Zhengzhou University Zhengzhou Henan ChinaDepartment of Radiation Oncology The First Affiliated Hospital of Zhengzhou University Zhengzhou Henan ChinaDepartment of Radiation Oncology The First Affiliated Hospital of Zhengzhou University Zhengzhou Henan ChinaDepartment of Radiation Oncology The First Affiliated Hospital of Zhengzhou University Zhengzhou Henan ChinaDepartment of Radiation Oncology The First Affiliated Hospital of Zhengzhou University Zhengzhou Henan ChinaDepartment of Radiation Oncology The First Affiliated Hospital of Zhengzhou University Zhengzhou Henan ChinaDepartment of Radiation Oncology The First Affiliated Hospital of Zhengzhou University Zhengzhou Henan ChinaDepartment of Radiation Oncology The First Affiliated Hospital of Zhengzhou University Zhengzhou Henan ChinaAbstract Objective To analyze the efficacy and adverse effects of anti‐PD‐1 immune checkpoint inhibitors aimed at nasopharyngeal carcinoma (NPC). Methods During the first stage of the study, using 40 patients with stage III/IVa NPC treated with anti‐PD‐1 immune checkpoint inhibitors in combination with chemoradiotherapy as a first‐line treatment (observation group) and 70 patients with NPC treated with chemoradiotherapy alone (control group). In the second stage of the study, 88 patients with NPC treated with immune checkpoint inhibitors were grouped according to the number of lines of immunotherapy, the number of times, and the types of application. Results Observation of the short‐term effects in the first stage indicated that the objective response rate (ORR) of the observation group and the control group against primary foci of NPC was 75.0% versus 40.0%; the mortality rate of the observation group was much lower than that of the control group. The overall first‐line treatment evaluation of the observation vs. control groups were as follows: ORR (67.5% vs. 38.6%); median PFS (17.52 vs. 17.21 months); and median OS (18.68 vs. 18.14 months), respectively (p < 0.05). The second stage of the study had an ORR of 53.4%, and the efficacy of immunotherapy was related to staging, timing, and frequency. Conclusion Anti‐PD‐1 immune checkpoint inhibitors combined with chemoradiotherapy as the first‐line treatment for nasopharyngeal carcinoma may improve patient outcomes significantly. Timing, frequency, and the type of immunotherapy exerted an effect on the efficacy of immunotherapy. Adverse effects that occurred during treatment were tolerable and controllable.https://doi.org/10.1002/cam4.7359immune checkpoint inhibitorsimmune‐related adverse eventsnasopharyngeal cancerPD‐1 |
| spellingShingle | Shuling Shi Bingyan Li Pengcheng Zhou Linhui Chen Huizhen Li Yingyi Wang Xiaoyu Deng Qianqian Dang Jingjing Wu Boya Zha Peihong Li Yingjuan Zheng Daoke Yang Analysis of the clinical efficacy and safety of anti‐PD‐1 immune checkpoint inhibitors in locally advanced nasopharyngeal cancer Cancer Medicine immune checkpoint inhibitors immune‐related adverse events nasopharyngeal cancer PD‐1 |
| title | Analysis of the clinical efficacy and safety of anti‐PD‐1 immune checkpoint inhibitors in locally advanced nasopharyngeal cancer |
| title_full | Analysis of the clinical efficacy and safety of anti‐PD‐1 immune checkpoint inhibitors in locally advanced nasopharyngeal cancer |
| title_fullStr | Analysis of the clinical efficacy and safety of anti‐PD‐1 immune checkpoint inhibitors in locally advanced nasopharyngeal cancer |
| title_full_unstemmed | Analysis of the clinical efficacy and safety of anti‐PD‐1 immune checkpoint inhibitors in locally advanced nasopharyngeal cancer |
| title_short | Analysis of the clinical efficacy and safety of anti‐PD‐1 immune checkpoint inhibitors in locally advanced nasopharyngeal cancer |
| title_sort | analysis of the clinical efficacy and safety of anti pd 1 immune checkpoint inhibitors in locally advanced nasopharyngeal cancer |
| topic | immune checkpoint inhibitors immune‐related adverse events nasopharyngeal cancer PD‐1 |
| url | https://doi.org/10.1002/cam4.7359 |
| work_keys_str_mv | AT shulingshi analysisoftheclinicalefficacyandsafetyofantipd1immunecheckpointinhibitorsinlocallyadvancednasopharyngealcancer AT bingyanli analysisoftheclinicalefficacyandsafetyofantipd1immunecheckpointinhibitorsinlocallyadvancednasopharyngealcancer AT pengchengzhou analysisoftheclinicalefficacyandsafetyofantipd1immunecheckpointinhibitorsinlocallyadvancednasopharyngealcancer AT linhuichen analysisoftheclinicalefficacyandsafetyofantipd1immunecheckpointinhibitorsinlocallyadvancednasopharyngealcancer AT huizhenli analysisoftheclinicalefficacyandsafetyofantipd1immunecheckpointinhibitorsinlocallyadvancednasopharyngealcancer AT yingyiwang analysisoftheclinicalefficacyandsafetyofantipd1immunecheckpointinhibitorsinlocallyadvancednasopharyngealcancer AT xiaoyudeng analysisoftheclinicalefficacyandsafetyofantipd1immunecheckpointinhibitorsinlocallyadvancednasopharyngealcancer AT qianqiandang analysisoftheclinicalefficacyandsafetyofantipd1immunecheckpointinhibitorsinlocallyadvancednasopharyngealcancer AT jingjingwu analysisoftheclinicalefficacyandsafetyofantipd1immunecheckpointinhibitorsinlocallyadvancednasopharyngealcancer AT boyazha analysisoftheclinicalefficacyandsafetyofantipd1immunecheckpointinhibitorsinlocallyadvancednasopharyngealcancer AT peihongli analysisoftheclinicalefficacyandsafetyofantipd1immunecheckpointinhibitorsinlocallyadvancednasopharyngealcancer AT yingjuanzheng analysisoftheclinicalefficacyandsafetyofantipd1immunecheckpointinhibitorsinlocallyadvancednasopharyngealcancer AT daokeyang analysisoftheclinicalefficacyandsafetyofantipd1immunecheckpointinhibitorsinlocallyadvancednasopharyngealcancer |